METHODS: An online survey was conducted among surgeons and urologists identified through the St. Jude Global Online Community Asia Pacific Pediatric Surgical Collaborations Group and participants of the St. Jude-VIVA Pediatric Surgical Oncology Symposium 2024.

RESULTS: Ninety-six of 99 respondents provided replies, together representing 11 countries and 51 institutions. The majority (n = 90, 93.8%) were pediatric surgeons, with 26.7% having had subspecialty training in urology or oncology; 60% had experience managing Wilms tumors for more than 5 years, though 64% performed less than three nephrectomies per year. A chemotherapy-first approach was specified by 31% of institutions, but employed by 40% of respondents in actual practice. Of those who practiced a chemotherapy-first approach, 44.8% did so without an initial biopsy. Notably, 38% of respondents and 55% of institutions did not adhere to a consistent protocol. Lymph node biopsy practices varied widely, with only 40.6% sampling routinely and 56.3% had ever experienced a tumor rupture during nephrectomy. Most (90%) perceived that Wilms tumors comprised 90% of all renal tumors in Asian children-contrary to known demographic data.